| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
V38034-1mg |
≥99% | ￥2370.00 |
货期：3-5天 | - | - | - | - |
|
V38034-2mg |
≥99% | ￥3680.00 |
货期：3-5天 | - | - | - | - |
|
V38034-5mg |
≥99% | ￥5890.00 |
货期：3-5天 | - | - | - | - |
|
V38034-10mg |
≥99% | ￥8560.00 |
货期：3-5天 | - | - | - | - |
|
V38034-25mg |
≥99% | ￥12300.00 |
货期：3-5天 | - | - | - | - |
|
V38034-50mg |
≥99% | ￥17200.00 |
货期：3-5天 | - | - | - | - |
|
| 靶点： | APJ | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 体内研究： | AM-8123 (100 mg/kg; p.o.) results in sustained improvement in systolic function and decreases both EDV and ESV as measured by echocardiography but not by the invasive pressure-volume conductance catheter at study termination. AM-8123 (0.035, 0.09, 0.9, and 9 mg/kg; i.v.) improves cardiovascular function. AM-8123 exhibits appreciably greater oral bioavailability in rats and dogs relative to pyr-apelin-13. AM-8123 infusion results in an increase in EF, SV, and dP/dt max at submicromolar unbound plasma concentrations with minimal change in HR, indicating that acute infusion of AM-8123 is associated with an improvement in several markers of cardiac function. AM-8123 is a more potent mediator of both ERK and AKT phosphorylation relative to pyr-apelin-13. |
||||||||||||||||||||
| 参考文献： | 1. Ason B, et al. Cardiovascular response to small-molecule APJ activation. JCI Insight. 2020;5(8):e132898. Published 2020 Apr 23. doi:10.1172/jci.insight.132898 | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京